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Costs were estimated by the UNU-Casemix Group (UNU-CBG) system, a top-down
costing system developed by the United Nations University-International Institute
for Global Health and the National University of Malaysia. The above costing sys-
tem was used in the countries included in this study. An episode of inpatient care
for any condition was defined as all treatments provided by the hospital from the
time of admission until discharge. Length of stay and cost per acute episode of MI
were identified for analysis. Local currency costs were converted to 2012 US$.
RESULTS: The average length of stay for a mild, moderate and severe episode of
acute MI in Indonesia was 6.0, 8.3 and 13.8 days respectively, compared to 5.8, 7.5
and 9.2 days in Malaysia and 4.5, 7.1 and 10.2 days in the Philippines. The average
cost of mild, moderate and severe acute MI in these countries were US $1075, US
$1698 andUS $2450 in Indonesia, US $1264, US $1616 andUS $1999 inMalaysia, and
US $1220, US $1927 and US $2779 in the Philippines. CONCLUSIONS: Our results
show that length of stay and treatment cost for an episode of acute MI varied
between countries and increased with clinical severity. Differences may be due to
factors such as health systems and reimbursement mechanisms. In addition, we
found that the available cost data is useful for analysis of health care costs in South
East Asia.
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OBJECTIVES: In light of the medicare savings debate in the US and AMNOG reform
in Germany, we aim to compare average branded factory price and average annual
cost of treatment for amiodarone and propafenone, the two most commonly pre-
scribed drugs for the treatment of arrhythmia, across 6 countries (EU top 5 and US).
METHODS:A quantitative analysis was performed using the average factory prices
for each branded active pharmaceutical ingredient (API) from IHS PharmaOnline
International (POLI) and average annual treatment costs from IHS World Markets
Cardiovascular and Metabolic service (WMCVM). We used dosing monographs to
calculate the total average dosing to accommodate for regional differences in cur-
rent treatmentmodalities. RESULTS: In the United States, the average price permg
for amiodarone is $0.006 and average annual cost of treatment is $2326. In the
Germany, UK, Italy, Spain and France, the average price per mg for amiodarone is
€0.025, £0.003, €0.003, €0.001 and €0.001, and average annual cost of treatment is
€9216, £1147, €973, €492, €365, respectively. In the United States, the average price
per mg for propafenone is $0.014 and average annual cost of treatment is $3480. In
the Italy, Spain, Germany, and United Kingdom, the average price per mg for
propafenone is €0.003, €0.001, €0.0009, £0.0005, and, and average annual cost of
treatment is €751, €380, €231, £124, respectively. CONCLUSIONS: That the price and
cost of amiodarone treatment is the highest in Germany is notable given the recent
launch of AMNOG. Amiodarone is one of themost common comparator for cardio-
metabolic drugs and its high price could allow for higher prices for newer market
entrants. The relative high price and cost of propafenone treatment in the United
States gives credence to proponents of health care savings who argue for system-
atic overhaul of drug prices.
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OBJECTIVES: To describe the real-world clinical complications associated with ve-
nous thromboembolism (VTE) and quantify the incremental direct all-cause and
disease-specific health care utilization and costs associated with VTE.METHODS:
Health insurance claims between January 2004 and December 2008 from the
IMPACTdatabasewere used. Adult patientswith an indexVTE diagnosis (deep vein
thrombosis [DVT], pulmonary embolism [PE], or both) were matched 1:1 with con-
trol patients without VTE. Each patient’s observation period began on the date of
the index VTE or corresponding date for controls and ended on the earlier of 1 year
after the study index date, the health plan disenrollment date, or December 31,
2008. The proportion of patients with recurrent VTE requiring hospitalization or
post-thrombotic syndrome (PTS)was calculated. All-cause incremental health care
costs associated with VTE and disease-specific costs related to VTE complications
were also reported. RESULTS: The VTE and no-VTE cohorts (16,969 subjects in each
group) were well matched for age, gender, comorbidities, and VTE risk factors. The
index VTE event was DVT, PE, or both in 12,711, 2473, and 1785 patients, respec-
tively. The risks of recurrent VTE requiring hospitalization and PTS during the
1-year follow-up period were 3.6% and 6.2%, respectively. Patients with VTE had
significantly higher average yearly all-cause costs compared to no-VTE patients
(mean [SD]: $33,531 [$70,393] versus $17,590 [$42,011], cost difference$15,941; 95%
CI14,819–17,012). Disease-specific health care costs related to VTE complications
represented 18.3% ($2913 of $15,941) of the all-cause cost difference between the
two groups. CONCLUSIONS: In this large matched-cohort study, VTE was associ-
ated with a 3.6% risk of hospitalization due to recurrence and a 6.2% risk of PTS at
1 year. VTE was also associated with significant health care cost burden—disease-
specific costs related to VTE complications represented nearly one-fifth of the in-
cremental all-cause costs associated with VTE.
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OBJECTIVES: To estimate the 1-year direct and indirect costs of ischemic stroke in
Chinese patients with atrial fibrillation (AF).METHODS:A cost-of-illness studywas
conducted through hospital chart review and a patient follow up survey. Costs
were estimated from the societal perspective. Three hundred hospital charts from
12 tier-3 hospitals and 6 tier-2 hospitals in 6 cities across China were randomly
selected and reviewed for cost of stroke during hospitalization from patients dis-
charged from January, 2009 to December, 2010 (discharge diagnosis of both, isch-
emic stroke and AF). Of those, 50 patients were followed up to collect the long-term
direct and indirect costs related to ischemic stroke in the year following discharge.
RESULTS:We report here results from two hospitals (N30): patients had a mean
age of 75 years and mean length of stay of 16 days (95%CI [14, 19]). Females
accounted for 43%. The mean time interval between stroke onset and hospitaliza-
tion was 24 hours (95%CI [14, 33]). The cohort scored on average 3 points (95%CI
[2, 4]) on the CHA2DS2-VASc, indicating a high risk of stroke considering patient
demographics and disease history. Average total 1-year costs of stroke manage-
mentwere estimated at 19,560.01 RMB (2010 costs; 4951.90US$), almost all ofwhich
was attributable to direct costs. Costs of inpatient care dominated direct costs,
representing 90.3% of the total direct costs. Average total costs during hospitaliza-
tion were estimated at 17,659.31 RMB (95%CI [13,538.39, 21,780.23]), 62.5% of
which was attributable to medication. CONCLUSIONS: The findings indicate that
ischemic stroke among AF patients are associated with high direct costs, imposing
a considerable burden on society. Hospital costs are the predominant contributor,
consistent with the current pattern of care in China, where patient care is usually
provided via hospitals.
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OBJECTIVES: To develop United States (US) cost model estimates for venous
thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary
embolism (PE). Total US costs were calculated as well as hospital-acquired, “pre-
ventable”, and indirect VTE costs.METHODS:A literature reviewwas performed to
determine VTE incidences, morbidity probabilities, case-fatality rates, and direct
medical and indirect costs. Indirect costs were derived from present value of life-
time earnings (PVLE) due to premature death. Two decision trees mapping PE and
DVT outcomes were developed, and cost models were constructed in Microsoft
Excel. The decision trees first contain primary VTE characteristics and outcomes:
hospital- or community-acquired; fatal versus non-fatal; readmission/recurrence
versus none; and instant versus non-instant death. Initially surviving patients are
at risk for associated morbidities: minor bleed; major bleed; heparin induced
thrombocytopenia; chronic thromboembolic pulmonary hypertension; post-
thrombotic syndrome; and resolution or no resolution of symptoms or death. The
average patient’s cost, the sum of each decision tree pathway’s probability-
weighted cost, weremultiplied by low and high annual PE and DVT incident events
to determine total cost ranges. All costs were adjusted to 2011 US dollars. Two
multi-way sensitivity analyses were conducted: one analysis has higher probabil-
ities and costs; the second introduces long term attack rates (LTAR), pooled inci-
dent and recurrent events, into the baseline and first multi-way sensitivity analy-
ses with only low VTE incidences. RESULTS: Annual US total base case (LTAR
sensitivity analysis), hospital-acquired, preventable, and indirect VTE costs range
from$13.4-27.0 ($15.3-34.3) billion, $8.9-18.0 ($10.2-25.3) billion, $4.5-14.0 ($5.1-12.7)
billion, and $4.5-9.8 ($5.6-11.7) billion, respectively. PE comprises the majority of
VTE costs. Indirect costs due to PVLE represent at least 33% of total VTE costs.
CONCLUSIONS: The United States could avoid substantial costs, morbidity and
mortality if effective VTE prophylactic strategies were implemented. This attain-
able goal would contribute to important health care reform.
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OBJECTIVES: Using longitudinal data, this study examined the determinants of
pharmaceutical expenditures for patients with hypertension, and the impact of
lifestyle andmarriage status changes on pharmaceutical expenditures.METHODS:
The longitudinal household components and the prescribedmedicine data ofMed-
ical Expenditure Panel Survey (MEPS) for year 2008 and 2009 were employed. Five
rounds of the survey were conducted for Panel 13 households between years 2008
and 2009. Only round 3 and round 5 surveys were used for this work because BMI
values were only included in these two rounds. I included individuals older than 18
years, not pregnant, with hypertension but no other comorbid conditions, andwho
had obtained a prescription for antihypertensive agents for essential hypertension
(ICD-9 code 401). The final panel data contained 1814 observations, among which
average agewas 53.65 years (SD13.49), the average age at the time of hypertension
diagnosis was 44.22 (SD13.43) years, 49.91% (SD0.50) were male. Ordinary Least
Square and Mixed Effect Model were employed to investigate the determinants of
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